Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 5.45B 4.84B 4.53B 4.12B 7.77B 525B 7.87B 54.76B 21.2B 267B 20.46B 20.02B 858B P/E 2026 *
-5.55x
P/E 2027 * -114x
Enterprise Value 5.63B 5B 4.68B 4.26B 8.02B 542B 8.13B 56.57B 21.9B 276B 21.14B 20.68B 887B EV / Sales 2026 *
8.08x
EV / Sales 2027 * 6.74x
Free-Float
98.34%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Mirum Pharmaceuticals, Inc.

1 day-0.26%
1 week-6.62%
Current month-2.01%
1 month-16.10%
3 months-33.31%
6 months-11.05%
Current year+6.04%
1 week 83.16
Extreme 83.155
91.25
1 month 83.16
Extreme 83.155
103.28
Current year 73.82
Extreme 73.82
130
1 year 63.23
Extreme 63.232
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 20/03/2019
Director of Finance/CFO 66 10/09/2023
President 48 15/01/2024
Director TitleAgeSince
Chairman 73 20/03/2019
Director/Board Member 55 06/11/2018
Director/Board Member 47 31/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
14/09/26 Sell

Chief Financial Officer

-9,943 0.0153%
02/09/26 Sell

Controller/Auditor

-658 0.0010%
01/09/26 Exercice

Founder

90,000 0.1386%
Change 5-day change 1-year change 3-year change Capi.($)
-0.26%-6.62%+16.74%+185.87% 5.45B
+1.19%-2.32%+41.00%+114.75% 1,025B
-0.31%-5.00%+38.54%+66.07% 623B
+0.18%-1.60%+9.95%+75.45% 459B
-0.01%-3.31%+60.71%+40.27% 355B
-0.82%-3.58%+22.19%+40.05% 336B
-1.31%-2.74%+12.02%+24.79% 270B
-1.00%-4.99%-4.24%+8.91% 247B
-0.51%-2.10%+36.48%+52.42% 220B
-1.08%-2.94%+32.50%+97.70% 183B
Average -0.43%-2.31%+26.59%+70.63% 372.37B
Weighted average by Cap. -0.07%-2.11%+31.12%+69.96%

Financials

2026 *2027 *
Net sales 697M 619M 579M 527M 993M 67.06B 1.01B 7B 2.71B 34.15B 2.62B 2.56B 110B 820M 728M 681M 620M 1.17B 78.9B 1.18B 8.23B 3.19B 40.18B 3.08B 3.01B 129B
Net income -926M -823M -769M -701M -1.32B -89.16B -1.34B -9.31B -3.6B -45.41B -3.48B -3.4B -146B -26.73M -23.74M -22.2M -20.23M -38.09M -2.57B -38.62M -269M -104M -1.31B -100M -98.19M -4.21B
Net Debt 181M 161M 150M 137M 258M 17.42B 261M 1.82B 704M 8.87B 679M 665M 28.5B 74.95M 66.57M 62.26M 56.73M 107M 7.22B 108M 753M 292M 3.68B 281M 275M 11.8B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
433
Date Price Change Volume
02/10/26 US$83.81 -0.13% 168,327
01/10/26 US$83.92 -1.82% 641,935
30/09/26 US$85.48 -2.35% 901,734
29/09/26 US$87.54 -0.48% 666,831
28/09/26 US$87.96 -1.94% 1,236,867
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
83.92USD
Average target price
145.79USD
Spread / Average Target
+73.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRM Stock